Cellectar Corp (CLRB) - שולי הרווח הגולמי

Cellectar Biosciences develops precision radiopharmaceuticals to combat rare tumors. The gross margin as a percentage of revenue demonstrates the business's ability to protect profits, with the current level sitting around 0.00. Proprietary PDC conjugates ensure leadership in the therapy of macroglobulinemia. Stringent FDA requirements and isotope complexities create significant barriers to entry for new players in the sector.
פילוחי מדדים פיננסיים ומדדי שוק עבור Cellectar Biosciences Inc (CLRB)

Gross margin is calculated as the ratio of the difference between revenue and cost of goods sold to total sales, allowing for an assessment of direct production efficiency. This metric reflects the ability of Cellectar Biosciences (CLRB) to monetize the unique radiopharmaceutical developments of highly qualified scientists, while gross margin variance captures the real-time assessment of the operating model's reaction to the cost of creating innovative drugs.